Letter from the Executive Director RUTLEDGE FOUNDATION 2

Exactly 6 years ago, I was sitting in my daughter Carley’s hospital room, watching the last few doses of cytotoxic chemotherapy enter her veins. I was overcome with unrest. Her treatment was nearing the end, and even though there was no evidence of disease, her body was weak from 11 months/14 rounds of chemotherapy and 33 rounds of radiation. We could not ignore the reality of her cancer returning, nor the dim reality that there were no curative treatment options available.

Thus began the Rutledge Foundation’s quest to fund research in the area of “next generation” therapies for pediatric and young adult sarcomas. In 2011 there were a few, dedicated researchers, who were doing preclinical work with targeted and immune-based therapies for Ewing sarcoma. Since then, we have followed and supported the most promising research. We have played a role in bringing 3 Ewing specific therapies into clinical trials. Two of these drugs are scheduled to open clinical trials this spring, and vaccine therapy is moving toward the next stages of FDA approval.  We are truly encouraged by the progress being made.

Our Vision is clear:  Eradicate teen and young adult cancer through education, early detection, and less toxic, targeted, life-saving therapies

We hope you will remain with us until our vision is realized.
Laura Rutledge

Grant Recipients

Mary Crowley Cancer Research Center/ Type II Targeted Therapy
January, November 2016

Mary Crowley Cancer Research Center Press Release December 5, 2016
Mary Crowley Advances New Targeted Investigational Therapy for Ewing Sarcoma

For more information on Ewing Type I Clinical Trial Click Here

Three years ago, the Rutledge Foundation initiated funding to develop a new drug that targets the gene that causes Ewing sarcoma. In early October, on the Monday after the Hearts of Gold Luncheon, the first patient began treatment in the Phase I Trial of Mary Crowley Cancer Research Center’s Targeted Therapy for Type I Ewing’s. If proven effective, this could be the first drug specifically developed to treat Type I Ewing sarcoma. More patients are scheduled to enroll in 2017….Read More

Moncrief Cancer Institute/ Onco-Fertility Preservation Program
June, December 2016
Lori Drew. Stephanie Lawrence.Laura Rutledge.Carolyn Roberts.Keith Argenbright left to right
The Rutledge Foundation is excited to announce it’s partnership with Moncrief Cancer Institute in its support of an Onco-fertility Preservation Program for patients diagnosed with cancer during their reproductive years. Often, patient fertility takes a back seat to immediate cancer treatment  and the window of opportunity for intervention is missed. The goal of the program is to provide 1) physician and patient education opportunities on fertility preservation and the treatment options available, 2) patient care coordination for fertility preservation treatment, and 3) financial assistance for fertility preservation treatment for underinsured and uninsured adolescent and young adult cancer patients. It is our hope that loss of fertility will soon be a side-effect of the past.

Children’s Cancer Therapy Development Institute
May 2016
The Nathalie Traller family established a fund with the Rutledge Foundation to honor Nathalie and her goal to find a cure for Aveolar Soft Part Sarcoma (ASPS).  With the help of family and friends, THE SHAVING OF THE GILBEY fundraiser, and the KICK ASPS 5K they raised $13,786.00.  The Traller family chose Children’s Cancer Therapy Development Institute in Beaverton, Oregon to be the recipient of their fund.  The Rutledge Foundation funded a research grant for a pilot project to develop pediatric ASPS cell lines from different years of disease progression for a female teenage patient. This research could be very helpful as a preclinical research tool to investigate new potential therapies for different stages of progression for ASPS.

UNT Health Science Center
April 2015
RUTLEDGE FOUNDATION 1On April 10, 2015, the Rutledge Foundation presented Dr. Andras Lacko and his team of researchers at UNT Health Science Center a check for $60,000 to further their research on a non-toxic lipoprotein delivery system that targets and destroys cancer cells. When asked why the Rutledge Foundation chose UNTHSC, Laura Rutledge said, “Dr. Lacko’s research appealed to us because he is using a natural process in the body as a vehicle for chemo, so it goes straight to the cancer without harming other cells.”

The donation will be used to upgrade the Lipoprotein Therapeutics Lab at UNTHSC, allowing for more space and a larger staff to support Dr. Lacko’s research that uses “good cholesterol” nanoparticles to selectively destroy tumors. This delivery system is anticipated to spare patients the toxic effects often experienced during and after treatment. He is studying ovarian and prostate cancer now. The hope is that this research will be used to treat Ewing sarcoma patients one day soon. “We are very fortunate to get this support,” Dr. Lacko said, “It allows us to continue doing what we believe will be helpful in the treatment of cancer.”


Mary Crowley Cancer Research Centers
December 2014/ January 2015

Families of Ewing Sarcoma patients have banded together from across the U.S. to raise money for the development of a new cancer therapy. Thirteen-year-old Sam Day and his family from Portland, Oregon, and Executive Director of the Rutledge Foundation, Laura Rutledge, from Ft. Worth, Texas, presented a check for $150,000 to Mary Crowley Cancer Research Center on December 16th, 2014. This check brings the total funds raised to $900,000 and closer to the goal of $1.1 Million needed to bring a new investigational therapy to patients in late 2015. Read full press release here.

Mary Crowley Cancer Research Center
January 2013
The Rutledge Foundation awarded $50,000 to the Mary Crowley Cancer Research Center to develop a targeted drug for Ewing sarcoma.  If successful, the drug will attack the cancer at the genetic control point.  The initial results have proven tumor knockdown in vitro.  They are currently testing the drug with mice.  By the end of 2013, they should have further results. Click here to read the full press release.